Anna Sf Lok

Anna Sf Lok

Auto-generated profile, based on publicly available information

Anna Sf Lok

Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2003 in Hepatology
Verified
Journal Article
Closed access
PDF file
CWChun-Tao Wai
Chun-Tao Wai
JGJoel K. Greenson
Joel K. Greenson
RFRobert J. Fontana
Robert J. Fontana
JKJohn D. Kalbfleisch
John D. Kalbfleisch
JMJorge A. Marrero
Jorge A. Marrero
ALAnna S.-F. Lok
Anna S.-F. Lok
Information on the stage of liver fibrosis is essential in managing chronic hepatitis C (CHC) patients. However, most models for predicting liver fibrosis are complicated and separate formulas are needed to predict significant fibrosis and cirrhosis. The aim of our study was to construct one simple model consisting of routine laboratory data to predict both significant fibrosis and cirrhosis among patients with CHC. Consecutive treatment–naive CHC patients who underwent liver biopsy over a 25–month period were divided into 2 sequential cohorts: training set (n = 192) and validation set (n = 78). The best model for predicting both significant fibrosis (Ishak score ≥ 3) and cirrhosis in the training set included platelets, aspartate aminotransferase (AST), and alkaline phosphatase with an area under ROC curves (AUC) of 0.82 and 0.92, respectively. A novel index, AST to platelet ratio index (APRI), was developed to amplify the opposing effects of liver fibrosis on AST and platelet count. The AUC of APRI for predicting significant fibrosis and cirrhosis were 0.80 and 0.89, respectively, in the training set. Using optimized cut–off values, significant fibrosis could be predicted accurately in 51% and cirrhosis in 81% of patients. The AUC of APRI for predicting significant fibrosis and cirrhosis in the validation set were 0.88 and 0.94, respectively. In conclusion, our study showed that a simple index using readily available laboratory results can identify CHC patients with significant fibrosis and cirrhosis with a high degree of accuracy. Application of this index may decrease the need for staging liver biopsy specimens among CHC patients.

27 August 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
ALAnna S. F. Lok
Anna S. F. Lok
BMBrian J. McMahon
Brian J. McMahon
Click on the article title to read more.

1 February 2007 in Hepatology
Verified
Journal Article
Closed access
PDF file
ALAnna S. F. Lok
Anna S. F. Lok
BMBrian J. McMahon
Brian J. McMahon

1 December 2001 in Hepatology
Verified
Journal Article
Closed access
PDF file
ALAnna S. F. Lok
Anna S. F. Lok
BMBrian J. McMahon
Brian J. McMahon
Opinion statement – All patients who test positive for hepatitis B virus (HBV) surface antigen (HBsAg) should be evaluated to determine the activity and severity of the infection. Assessment includes tests of disease activity (aspartate transaminase, alanine aminotransferase), tests of liver function (bilirubin, albumin, prothrombin time), and tests of replication status (hepatitis B early antigen [HBeAg], antibody to HBe, HBV DNA titer, and hepatitis D virus antibody). An ultrasound is recommended to assess for signs of cirrhosis and to exclude focal lesions in the liver. – In patients with abnormal liver enzyme levels (aspartate aminotransferase, alanine aminotransferase), a liver biopsy is recommended to assess the stage of disease (amount of fibrosis) and to determine the urgency and need for antiviral therapy. – Interferon alfa and lamivudine are the two antiviral therapies currently available. There are pros and cons associated with the use of either drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended. – Patients with abnormal liver enzyme levels, indices of active viral replication (positive HBV DNA, with or without positive HBeAg), and compensated liver disease are candidates for treatment with interferon or lamivudine. – For patients with abnormal liver enzyme levels, indices of active viral replication (positive HBV DNA, with or without positive HBeAg), and decompensated liver disease, the treatment of choice is lamivudine. Concurrently, these patients should be considered for liver transplantation referral. – There are a number of new antiviral agents currently under evaluation in clinical trials. Combination therapy for chronic HBV infection is anticipated. The use of two or more anti-HBV drugs can be expected to enhance efficacy and reduce the likelihood of drug resistance.

1 December 2003 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ALAnna S.F Lok
Anna S.F Lok
Ching-Lung LaiChing-Lung Lai
Ching-Lung Lai
NLNancy Leung
Nancy Leung
GYGuang-Bi Yao
Guang-Bi Yao
ZCZhen-Yu Cui
Zhen-Yu Cui
MCMary Castiglia
Mary Castiglia

9 February 2023 in The Lancet
Verified
Journal Article
Closed access
WJWen-Juei Jeng
Wen-Juei Jeng
GPGeorge V Papatheodoridis
George V Papatheodoridis
ALAnna S F Lok
Anna S F Lok